Trending Now
Synthetic Biologics Inc. (NYSEAMERICAN: SYN) Enters Definitive Agreement To Acquire CVN...
Synthetic Biologics Inc. (NYSEAMERICAN: SYN) has signed a definitive agreement to purchase VCN Biosciences S.L (VCN), which is creating a novel oncolytic adenovirus platform...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Revance Therapeutics Inc (NASDAQ:RVNC) surges while rest of the Wall Street...
Revance Therapeutics Inc (NASDAQ:RVNC) managed to gain 5.18% while Dow tumbled 500 points on Friday to end September down nearly 9%.
MAKE IT MODERN
LATEST REVIEWS
Apple Inc (NASDAQ:AAPL) is heading towards 300 and here’s why
China easing triggered a rally in the market today. I think AAPL probably wants $300 so I might be a little early...
MAKE IT MODERN
PERFORMANCE TRAINING
SIGA Therapeutics Inc. (NASDAQ: SIGA) Reports Q1 2022 Financial Results With Product Sales of...
SIGA Therapeutics Inc. (NASDAQ: SIGA) has announced its Q1 2022 financial results and for the six months ending June 30, 2022. The company reported...
Alnylam Pharmaceuticals, Inc. (ALNY): Pioneering RNAi Therapeutics with Vutrisiran Expansion
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a trailblazer in RNAi therapeutics, closed at $237.97 on December 27, marking a modest decline of 1.87%...
Xenon Pharmaceuticals (XENE) could rally based on XEN1101
Xenon Pharmaceuticals (XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) And Argenx Expand Their Partnership And License Deal For ENHANZE®...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on October 6 that it is expanding its partnership and license agreement with Argenx, allowing them to continue working...
Wall Street set for another red day as rates surge on September’s jobs report...
Wall Street is waking up to the news of slowed job growth in September as payrolls rose just 263,000 amid Fed rate...
MAKE IT MODERN
